| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 |
| Sales | 790 | 440 | 860 | 2,590 | 9,790 |
| Sales Growth | +79.55% | -48.84% | -66.80% | -73.54% | +4.37% |
| Net Income | -7,510 | -28,490 | -12,880 | -20,060 | -20,700 |
| Net Income Growth | +73.64% | -121.20% | +35.79% | +3.09% | +24.26% |
Midatech Pharma ADR (MTP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Midatech Pharma Plc is focused on the discovery and development of pharmaceutical products of nanomedicine. The Company's product candidates, which are in clinical and pre-clinical development, are Transbuccal Insulin, glucagon-like-peptide, GLP-1/Insulin Combination, Q-Exenatide and Q-Octreotide. Midatech Pharma Plc is based in Abingdon, the United Kingdom.